within Pharmacolibrary.Drugs.ATC.L;

model L01XK01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.68,
    Cl             = 8.6 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,
    adminCount     = 1,
    Vd             = 0.158,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006333333333333333,
    Tlag           = 19.8
  );

  annotation(Documentation(
    info ="<html><body><p>Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor used in the treatment of certain types of cancers, including ovarian, breast, pancreatic, and prostate cancers with BRCA mutations. It is approved for use in multiple countries, including the US and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult cancer patients, both sexes, after oral administration of olaparib 300 mg (tablet formulation) twice daily.</p><h4>References</h4><ol><li><p>Plummer, R, et al., &amp; Molife, LR (2015). Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. <i>Cancer chemotherapy and pharmacology</i> 76(4) 723–729. DOI:<a href=&quot;https://doi.org/10.1007/s00280-015-2836-2&quot;>10.1007/s00280-015-2836-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26242220/&quot;>https://pubmed.ncbi.nlm.nih.gov/26242220</a></p></li><li><p>Rolfo, C, et al., &amp; Dean, E (2015). Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors. <i>Advances in therapy</i> 32(6) 510–522. DOI:<a href=&quot;https://doi.org/10.1007/s12325-015-0214-4&quot;>10.1007/s12325-015-0214-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26048134/&quot;>https://pubmed.ncbi.nlm.nih.gov/26048134</a></p></li><li><p>Griguolo, G, et al., &amp; Conte, P (2020). Olaparib for advanced breast cancer. <i>Future oncology (London, England)</i> 16(12) 717–732. DOI:<a href=&quot;https://doi.org/10.2217/fon-2019-0689&quot;>10.2217/fon-2019-0689</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32249603/&quot;>https://pubmed.ncbi.nlm.nih.gov/32249603</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XK01;
